Table 2 The distribution of subtypes between the training cohort and the validation cohort
Group | All patients (n = 1209) | P | Patients with the five major histological subtypes (n = 1039) | P | ||
|---|---|---|---|---|---|---|
| Â | Training cohort | Validation cohort | Â | Training cohort | Validation cohort | Â |
HGSC | 451 (53.31%) | 194 (53.44%) | 0.966 | 451 (62.04%) | 194 (62.18%) | 0.965 |
Non-HGSC | 395 (46.69%) | 169 (46.56%) | 276 (37.96%) | 118 (37.82%) | ||
MC | 55 (6.50%) | 24 (6.61%) | 0.943 | 55 (7.57%) | 24 (7.69%) | 0.944 |
Non-MC | 791 (93.50%) | 339 (93.39%) | 672 (92.43%) | 288 (92.31%) | ||
CC | 93 (10.99%) | 40 (11.02%) | 0.989 | 93 (12.79%) | 40 (12.82%) | 0.990 |
Non-CC | 753 (89.01%) | 323 (88.98%) | 634 (87.21%) | 272 (87.18%) | ||
EN | 77 (9.10%) | 33 (9.09%) | 0.995 | 77 (10.59%) | 33 (10.58%) | 0.994 |
Non-EN | 769 (90.90%) | 330 (90.91%) | 650 (89.41%) | 279 (89.42%) | ||
LGSC | 50 (5.91%) | 22 (6.06%) | 0.919 | 50 (6.88%) | 22 (7.05%) | 0.920 |
Non-LGSC | 796 (94.09%) | 341 (93.94%) | 677 (93.12%) | 290 (92.95%) | ||